Drugs / tumor neoantigen specific T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06431529 | Apr 2024 → Mar 2025 | soft tissue neoplasm | JIANG LONGWEI | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tumor neoantigen specific T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06431529 ↗ |
| Known as | NeoT | “The final product For tumor neoantigen specific T cells (NeoT).” NCT06431529 ↗ |
| Modality | Cell therapy | “The tumor neoantigen specific T cells will be infused intravenous into patients.” NCT06431529 ↗ |
| Route | Intravenous | “infused intravenous into patients” NCT06431529 ↗ |